Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN1400 · 1 trial · 1 indication
Safety will be assessed through analysis of laboratory data, physical examination findings and vital signs according to the schedule of assessments, in addition to the spontaneous reporting of adverse events according to CTCAE version 4.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Dosing regimen 1: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab |
| Cohort 2 | EXPERIMENTAL | Dosing regimen 2: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab |
| Cohort 3 | EXPERIMENTAL | Dosing regimen 3: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab |
| Name | Type | Description |
|---|---|---|
| REGN1400 | DRUG | - |
| Erlotinib | DRUG | - |
| Cetuximab | DRUG | - |
Inclusion Criteria include, but are not limited to, the following: 1. Confirmed diagnosis of certain unresectable or metastatic cancers 2. Adequate Eastern Cooperative Oncology Group (ECOG) performance status 3. Adequate hepatic, renal and bone marrow function 4. Resolution of toxicity from prior t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
REGN1400 is an investigational small molecule being developed by Regeneron Pharmaceuticals for the treatment of cancer. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in patients.
REGN1400 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol REGN. The company is conducting clinical trials to evaluate the drug's safety and potential efficacy in treating cancer.
REGN1400 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied in a completed Phase 1 trial to assess its safety, tolerability, and preliminary efficacy in patients with cancer.
REGN1400 has been studied in one clinical trial, identified by the identifier NCT01727869. This was a Phase 1 study that evaluated REGN1400 alone and in combination with erlotinib or cetuximab in patients with certain types of cancer. The trial, which enrolled 56 participants, has been completed.
No, REGN1400 is a distinct investigational drug. In the clinical trial NCT01727869, REGN1400 was studied both alone and in combination with erlotinib or cetuximab, which are separate cancer medications. The trial was designed to evaluate the safety and efficacy of REGN1400 when used by itself or alongside these other treatments.